·First generic to be marketed in China ·Included in the National Essential Drug List and National Reimbursement Drug List ·First-line treatment for bronchial asthma ·Supported by the National Science and Technology Major Project for "Innovative Drug Research and Development"

*For contraindications and adverse reactions, please see the package insert

·First generic to be marketed in China ·Independently developed API, obtained a Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP) from the European Directorate for the Quality of Medicines & HealthCare ·An important antibacterial drug recommended by multiple authoritative domestic and international guidelines for the treatment of multidrug-resistant gram-negative organism infections

*For contraindications and adverse reactions, please see the package insert

·First generic drug in China ·Once-daily administration ·Tiotropium is a core recommended drug in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines ·Included in both the National Reimbursement Drug List and the National Essential Drug List, covering over 3,000 public hospitals

*For contraindications and adverse reactions, please see the package insert

·First domestically produced tulobuterol transdermal patch ·Protects patients of all ages, including the elderly, children, and adults ·Breakthrough in 24-hour precision controlled-release and treatment of nocturnal symptoms ·Tulobuterol patches are recommended as a long-term treatment for asthma patients in the Japanese asthma guidelines

*For contraindications and adverse reactions, please see the package insert

·Preferred drug for upper respiratory tract infection ·First cefaclor compound preparation in China ·Winner of awards such as "Jiangsu Provincial Famous Trademark" and "High-Tech Product Technology Certification"

*For contraindications and adverse reactions, please see the package insert